Analysis of the progression-free survival of CLL patients who received first-line bendamustine-rituximab therapy depending on the elimination rate of the minimum residual disease and mutational status IGHV genes

Autor:	T. Chatalava, E. Tolstopiatova, E. Stadnik, T. Nikulina, N. Timofeeva, V. Strugov, A. Rumyantsev, I. Miroliubova, Y. Virz, A. Zaritskey
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry First line Hematology Disease Bendamustine/rituximab Internal medicine medicine Mutational status Progression-free survival business IGHV@ Gene
Zdroj:	Leukemia Research. 85:S26
ISSN:	0145-2126
DOI:	10.1016/s0145-2126(19)30258-9
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5d9ff57e0f2c6d0c62b0f0307320bd23 https://doi.org/10.1016/s0145-2126(19)30258-9 Zobrazit plný text záznamu Full Text from ScienceDirect